Alternating Hemiplegia of Childhood FoundationAlternating Hemiplegia of Childhood Foundation

Donate/

Menu

  • Home
  • About AHC
    • What is AHC
    • AHCF Can Help
    • Genetic Testing for AHC
    • Medication
    • What AHC Looks Like
    • Patient Care
    • Family Care
      • ABLE Act
    • Compounding Conditions
    • Glossary
  • Research
    • Research Projects
      • AAV Project
      • Natural History Database Project
    • Research Studies
    • Databases
    • AHC Bibliography
    • AHC in Charts
    • Grant Requests
  • The Foundation
    • Overview
    • Board of Directors
    • Medical Advisory Board
    • Policies and Info
      • Website Term & Conditions
      • Copyright Statement
      • Trademarks & Servicemarks
      • Privacy Policy
      • Conflict of Interest Policy
      • Financials
  • Fundraising
    • Contribute
    • Fundraising Overview
      • Media Resources
    • Where Funds are Directed
    • Hosting an Event
    • Fundraising Ideas
    • Fundraising Resources
  • Community
    • Engage
    • Webinar Series
    • Get Involved
      • Volunteer
      • Fundraise
      • Contribute
    • Who is AHC?
    • Family Meetings
      • New Jersey 2018
      • Indianapolis 2016
    • AHC Organizations
  • Resources
    • AHCF Can Help
    • Webinar Series
    • Fundraising Resources
    • Media Resources
    • Glossary
    • Helpful Links
    • Site Map
  • Contact us!

AHCF signs letter opposing changes to Orphan Drug Act

 Posted on July 22, 2013 by jmarsz

 Leave a Comment

As a Member Organization of NORD,  AHCF  has signed a letter to the House Ways & Means Committee and Senate Finance Committee opposing measures to reduce the tax credit as one of the incentives of the Orphan Drug Act. The House and Senate are considering measures that could eliminate or reduce the tax credit that is one of the important incentives in the Orphan Drug Act to encourage the development of treatments for people with rare diseases.  NORD strongly opposes this, and we will be signing onto a letter (see below) to be sent to the chairs and ranking members of the House Ways & Means Committee and Senate Finance Committee. For 30 years, NORD has been fighting to keep the Orphan Drug Act safe from those who might wish to change it.   TEXT OF THE LETTER: Dear Chairmen Camp and Baucus and Ranking Members Levin and Hatch: The undersigned organizations represent millions of patients suffering from rare diseases.  We are writing to express our strong support for the Orphan Drug Tax Credit (ODTC).  We know that Congress is developing tax reform proposals and we strongly urge you to keep this critical tax credit in place. Under the ODTC, drug manufacturers can claim a tax credit of 50% of the qualified costs of clinical research and drug testing of orphan drugs (drugs for diseases affecting 200,000 Americans or less).   The ODTC is part of a package of provisions enacted in 1983 in the Orphan Drug Act that provide incentives for drug companies to develop products for rare diseases.  This legislation has been extremely successful. In the decade before the Orphan Drug Act, only ten medicines were developed by industry for rare diseases.  Since passage, however, more than 2,700 potential treatments have entered the research pipeline as orphan products and more than 300 have been approved by the FDA.  Importantly, these products are often lifesaving; many orphan diseases are seriously debilitating and eventually fatal. Despite this progress, there are approximately 7,000 rare diseases affecting about 30 million people in the US, many of them children.  Nearly 95% of these diseases have no cures or treatments.  The ODTC provides necessary incentives for companies to embark on research and development projects to develop treatments to help patients suffering from these diseases.  In so doing, the Orphan Tax Credit literally saves lives. Many of our members have already benefited from the research and product development that has been spurred by the ODTC, but more work needs to be done.  Millions of patients are relying on the development of new treatments and cures.  The ODTC has been – and will remain – essential to these efforts. Thank you for your attention to this important matter.
Facebook0
Twitter0
Google+0
LinkedIn0
Pinterest0
Tweet

 Category: Foundation Updates      Tags:

← 2013 AHCF Grant awarded to Vanderbilt University
AHC author writes children’s book →

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

A donation now can change the future for these children and families, before it is too late.

Become a fundraiser with our convenient peer-to-peer platform.

Foundation Updates
  • Race for hope
  • New Race Gear
  • Let’s Party
  • We need you!
  • RACE to END AHC
GreatNonprofits
Contact Us
Alternating Hemiplegia of Childhood Foundation 2000 Town Center Suite 1900 Southfield, MI 48075
(313) 663-7772
Say what? Translate here.
Newsletter Subscription
Subscribe to our Email Newsletter
Our Partners
We’re Doing All Right!
Alternating Hemiplegia of Childhood Foundation Inc Nonprofit Overview and Reviews on GreatNonprofits
Volunteer. Donate. Review.

Copyright © 2023 · All Rights Reserved · Alternating Hemiplegia of Childhood Foundation